1.0Research for Rarehttps://www.research4rare.de/en/mroeselehttps://www.research4rare.de/en/author/mroesele/CARPuD 2 - Research for Rarerich600338<blockquote class="wp-embedded-content" data-secret="OsL6c7c6PN"><a href="https://www.research4rare.de/en/alumni/carpud-2/">CARPuD 2</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://www.research4rare.de/en/alumni/carpud-2/embed/#?secret=OsL6c7c6PN" width="600" height="338" title="“CARPuD 2” — Research for Rare" data-secret="OsL6c7c6PN" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script>
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
//# sourceURL=https://www.research4rare.de/wp-includes/js/wp-embed.min.js
</script>
Only limited or no therapeutic options are available for the genetic diseases α1-antitrypsin deficiency, cystic fibrosis, and surfactant deficiencies. These usually lethal pulmonary diseases severely impair the human respiratory tract. So far, lung transplantation is the only therapeutic option when terminal organ failure occurs. The generation of induced pluripotent stem cells (iPSCs) opens new avenues […]